U.S. markets closed
  • S&P Futures

    +25.50 (+0.78%)
  • Dow Futures

    +221.00 (+0.84%)
  • Nasdaq Futures

    +74.50 (+0.67%)
  • Russell 2000 Futures

    +11.60 (+0.75%)
  • Crude Oil

    +0.21 (+0.56%)
  • Gold

    +0.60 (+0.03%)
  • Silver

    +0.15 (+0.63%)

    +0.0008 (+0.07%)
  • 10-Yr Bond

    +0.0030 (+0.39%)
  • Vix

    +6.93 (+20.78%)

    +0.0009 (+0.07%)

    +0.0320 (+0.03%)

    -14.83 (-0.11%)
  • CMC Crypto 200

    -10.61 (-3.89%)
  • FTSE 100

    -146.19 (-2.55%)
  • Nikkei 225

    -170.54 (-0.73%)

Chembio’s French Partner AAZ-LMB Wins Prix Galien International for Best Medical Technology with autotest VIH®

MEDFORD, N.Y., Dec. 06, 2018 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced that its French HIV self-test partner, AAZ-LMB, was awarded the 2018 Prix Galien International for Best Medical Technology. The Prix Galien, regarded as the equivalent of the Nobel Prize in biopharmaceutical and medical technology research, is awarded annually by The Galien Foundation to recognize outstanding achievements in improving the human condition through the development of innovative drugs and other treatments.

“The Chembio team would like to congratulate AAZ on receiving this prestigious award and for their dedication to the promotion of HIV Self-Testing,” said John Sperzel, Chembio’s Chief Executive Officer. “AAZ is a great advocate for HIV self-testing, and we look forward to continuing to support their efforts.”

AAZ manufactures the autotest VIH® in France, which incorporates Chembio’s components from SURE CHECK® HIV 1/2 Assay, and currently markets its product in 17 countries throughout Europe. To expand its HIV self-test business into Africa, Chembio has initiated trials for WHO prequalification for its SURE CHECK® HIV Self-Test product.

“We are honored to receive the 2018 Prix Galien International for Best Medical Technology,” said Dr. Joseph Coulloc'h, AAZ’s founder and President. “We remain dedicated to our mission of increasing access to screening self-tests and looking forward to ongoing collaboration with Chembio.”

About Chembio Diagnostics
Chembio Diagnostics, Inc. is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases. The company’s patented DPP® technology platform, which uses a small drop of blood from the fingertip, provides high-quality, cost-effective results in approximately 15 minutes. Coupled with Chembio’s extensive scientific expertise, its novel DPP® technology offers broad market applications beyond infectious disease, a number of which are under active development with collaboration partners. Chembio’s products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers.

Headquartered in Medford, NY, Chembio is registered with the U.S. Food and Drug Administration (FDA) as well as the U.S. Department of Agriculture (USDA), and is certified for the global market under the International Standards Organization (ISO) directive 13485. Learn more at www.chembio.com.

Media contact:

Lynn Pieper Lewis
Gilmartin Group
(415) 937-5402